Melphalan Ratiopharm

Melphalan Hydrochloride, the active ingredient in Melphalan Ratiopharm, is an alkylating agent (nitrogen mustard) presented as an injectable solution for intravenous use. It treats multiple myeloma, ovarian cancer, malignant melanoma, and neuroblastoma in adult and pediatric patients.

GNH USA supplies Melphalan Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Melphalan is an alkylating chemotherapy agent used in the treatment of several solid tumours and hematologic malignancies.

Multiple myeloma: induces remission and prolongs survival in patients with refractory disease. Ovarian cancer: used as part of combination regimens to reduce tumour burden. Malignant melanoma: employed in high‑dose protocols for advanced disease. Neuroblastoma: administered in intensive chemotherapy schedules for high‑risk disease.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during treatment. - Myelosuppression: decreased white blood cells, red cells, and platelets. - Fatigue: general tiredness and reduced energy. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers after treatment. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: acute kidney injury in susceptible patients.

Before initiating Melphalan therapy, several safety considerations should be reviewed.

Baseline blood counts: obtain complete blood count to assess marrow reserve. Renal function: evaluate serum creatinine and glomerular filtration rate. Hepatic function: check liver enzymes and bilirubin levels. Pregnancy status: avoid use in pregnant women unless benefits outweigh risks. Concomitant myelosuppressive drugs: monitor closely when combined with other cytotoxics. Store at ambient temperature: keep in original container, protect from light and moisture.

Melphalan can interact with other medicines, affecting its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection due to immunosuppression. - Strong CYP450 inducers: reduce plasma concentration of melphalan. - Anticoagulants (e.g., warfarin): increase bleeding risk when combined with melphalan‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely): - Other alkylating agents: additive myelosuppression. - Granulocyte colony‑stimulating factors: may modify blood count recovery. - Nephrotoxic drugs (e.g., aminoglycosides): heighten risk of renal impairment.